ASTRAZENECA PLC (AZN) Form 6-K — Aug 17, 2026
AstraZeneca and Daiichi Sankyo announced positive high-level results from the Phase III DESTINY-Lung04 trial, with Enhertu (trastuzumab deruxtecan) demonstrating a statistically significant and clinically meaningful improvement in progression-free survival versus global standard of care as a first-line treatment for HER2-mutant advanced non-small cell lung cancer. It is the first HER2-directed medicine to achieve this in a Phase III trial in the first-line setting. The trial enrolled 454 patients randomised 1:1 against platinum-pemetrexed chemotherapy plus pembrolizumab, and the safety profile was consistent with Enhertu's known profile with no new safety concerns identified.
Key figures
- Dose
- 5.4 mg/kg
- Comparator arm
- Platinum-pemetrexed doublet chemotherapy plus pembrolizumab
- Primary endpoint
- Progression-free survival assessed by blinded independent central review (met)
- Trial enrollment
- 454
- Collaboration start
- March 2019
- Randomization ratio
- 1:1
- Global lung cancer cases 2024
- approximately 2.6 million new cases
- Metastatic nsclc 5yr survival
- approximately 10%
- Global lung cancer deaths 2024
- estimated 1.8 million deaths
- Her2 mutation prevalence nsclc
- 2-4% of NSCLC patients
- Enhertu nsclc approval footprint
- approved in more than 80 countries for previously treated HER2-mutant NSCLC
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.